The Global Ipatasertib Market was valued at USD 315.2 Million in 2023 and is projected to reach USD 647.8 Million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 10.8% during the forecast period (2024–2030). This robust growth is primarily driven by the escalating global incidence of cancer, particularly prostate and breast cancers, accelerated clinical trial activities, and the increasing adoption of targeted therapy regimens that include AKT inhibitors.

As the oncology landscape increasingly focuses on precision medicine and overcoming treatment resistance, the development of targeted small molecule inhibitors like Ipatasertib has gained significant momentum. In this analysis, we profile the Top 10 Companies in the Ipatasertib Market—a combination of pharmaceutical giants, specialized chemical suppliers, and innovative biotech firms shaping the future of AKT pathway inhibition.

Download FREE Sample Report:
Global and Regional IpatasertibMarket – View in Detailed Research Report

---

🔟 1. Roche (Genentech)

Headquarters: Basel, Switzerland
Key Offering: Ipatasertib (GDC-0068) for clinical development

Roche, through its subsidiary Genentech, is the original developer of Ipatasertib and holds the key patents for this investigational AKT inhibitor. The company is conducting extensive Phase II and III clinical trials, particularly in combination with other therapies for metastatic castration-resistant prostate cancer (mCRPC) and triple-negative breast cancer (TNBC).

Clinical Development Initiatives:

• Leading the IPATential150 Phase III trial in prostate cancer

• Investigating combinations with Atezolizumab (Tecentriq) in multiple solid tumors

• Committed to advancing biomarker-driven cancer therapies

---

9️⃣ 2. Abcam plc

Headquarters: Cambridge, United Kingdom
Key Offering: High-purity Ipatasertib for research use

Abcam is a leading global supplier of research reagents, including high-quality Ipatasertib for preclinical and basic research. The company provides well-characterized batches of the compound, supporting academic institutions and biopharmaceutical companies in their early-stage drug discovery and mechanism-of-action studies.

Research Support Initiatives:

• Comprehensive analytical data (HPLC, MS, NMR) for all batches

• Global distribution network ensuring rapid delivery to researchers

• Technical support for assay development using AKT pathway inhibitors

Download FREE Sample Report:
Global and Regional IpatasertibMarket – View in Detailed Research Report

---

8️⃣ 3. Cayman Chemical Company

Headquarters: Ann Arbor, Michigan, USA
Key Offering: Ipatasertib for biochemical and cellular research

Cayman Chemical is a prominent supplier of biochemicals for research, offering Ipatasertib as part of its extensive portfolio of kinase inhibitors. The company serves pharmaceutical companies, academic research labs, and government agencies worldwide with high-purity compounds for signal transduction research.

Quality Assurance Initiatives:

• Rigorous quality control with multiple analytical techniques

• Batch-specific certificate of analysis for research reproducibility

• Support for high-throughput screening campaigns

---

7️⃣ 4. Selleck Chemicals

Headquarters: Houston, Texas, USA
Key Offering: Ipatasertib (Selleckchem catalog item S2808)

Selleck Chemicals specializes in providing high-quality inhibitors, agonists, and antagonists for life science research. Their Ipatasertib offering is widely used in cancer biology studies, particularly in research focused on the PI3K/AKT/mTOR signaling pathway and its role in tumorigenesis.

Research Enablement Initiatives:

• Large-scale supply capabilities for screening libraries

• Regularly updated product information with latest research citations

• Global logistics network serving over 50 countries

---

6️⃣ 5. MedChemExpress (MCE)

Headquarters: Monmouth Junction, New Jersey, USA
Key Offering: Ipatasertib (HY-15186) for research applications

MedChemExpress provides Ipatasertib as part of its comprehensive collection of bioactive small molecules. The company has established itself as a reliable supplier for the global research community, offering competitive pricing and robust technical support for studies involving AKT inhibition.

Customer Support Initiatives:

• Bulk quantity discounts for large-scale research projects

• Regular purity verification using HPLC and mass spectrometry

• Detailed protocol support for cellular efficacy studies

---

5️⃣ 6. BioVision Inc.

Headquarters: Milpitas, California, USA
Key Offering: Ipatasertib for cancer research and drug discovery

BioVision offers Ipatasertib through its extensive catalog of life science research products. The company focuses on providing high-quality biochemicals and reagents that enable researchers to study cellular pathways and develop novel therapeutic strategies for cancer treatment.

Scientific Support Initiatives:

• Comprehensive product documentation with application notes

• Collaborations with academic institutions for method development

• Stable supply chain ensuring consistent product availability

Download FREE Sample Report:
Global and Regional IpatasertibMarket – View in Detailed Research Report

---

4️⃣ 7. BOC Sciences

Headquarters: Shirley, New York, USA
Key Offering: Ipatasertib API and research-grade material

BOC Sciences provides Ipatasertib for both research and development purposes. The company supports pharmaceutical companies and research institutions with bulk quantities of the compound, along with custom synthesis services for analog development and structure-activity relationship studies.

Custom Synthesis Initiatives:

• Scale-up capabilities from milligram to kilogram quantities

• Analytical method development and validation services

• Regulatory support for preclinical development packages

---

3️⃣ 8. TargetMol Chemicals Inc.

Headquarters: Boston, Massachusetts, USA
Key Offering: Ipatasertib (T6238) for high-throughput screening

TargetMol specializes in providing bioactive compounds for drug discovery and development. Their Ipatasertib product is extensively used in phenotypic screening assays and target validation studies, particularly in oncology research programs focused on signal transduction inhibition.

Screening Support Initiatives:

• Integration into customized screening libraries

• Strict quality control for assay reproducibility

• Technical support for assay optimization and validation

---

2️⃣ 9. AdooQ Bioscience

Headquarters: Irvine, California, USA
Key Offering: Ipatasertib (A11368) for research applications

AdooQ Bioscience offers Ipatasertib as part of its focused portfolio of kinase inhibitors and cancer research compounds. The company provides researchers with high-purity materials supported by comprehensive analytical data, facilitating reproducible scientific investigations into AKT signaling.

Research Reproducibility Initiatives:

• Detailed batch-specific analytical certificates

• Stability studies and proper storage recommendations

• Active customer engagement for application support

---

1️⃣ 10. APExBIO Technology LLC

Headquarters: Houston, Texas, USA
Key Offering: Ipatasertib (B6256) for biochemical and cellular research

APExBIO provides Ipatasertib to the global research community, supporting studies on PI3K/AKT pathway dysregulation in cancer. The company emphasizes product quality and customer service, making it a preferred supplier for many academic and industrial research laboratories.

Quality Enhancement Initiatives:

• Continuous quality improvement based on researcher feedback

• Competitive pricing structures for academic researchers

• Efficient global distribution network

Get Full Report Here:
Global and Regional IpatasertibMarket – View in Detailed Research Report

---

🔬 Outlook: The Future of Ipatasertib in Precision Oncology

The Ipatasertib market is at a pivotal stage of development, transitioning from clinical research to potential commercialization. While current usage is predominantly in research settings, successful completion of ongoing Phase III trials could significantly expand the market into therapeutic applications.

📈 Key Trends Shaping the Market:

• Expansion of biomarker-driven clinical trials in multiple cancer indications

• Growing research on combination therapies to overcome treatment resistance

• Increasing investment in AKT pathway research across academic and industrial sectors

• Advancements in companion diagnostic development for patient stratification

The companies profiled above are not only supplying critical research tools—they’re enabling the next generation of targeted cancer therapies that could transform patient outcomes in difficult-to-treat malignancies.

Get Full Report Here:
Global and Regional IpatasertibMarket – View in Detailed Research Report